{
  "docId": "019dd923-622c-750b-8b9a-4b91788fc785",
  "docSlug": "5fadb686cc03",
  "documentTitle": "Twist Bioscience (TWST)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-11-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 93,
  "pageCount": 236,
  "prevPage": 92,
  "nextPage": 94,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a combination of summary text and a direct quote from an IDT ex-regional sales manager to frame the company's technology as a 'self-defeating gimmick'.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-4b91788fc785/93",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785#slide-93",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "However, the workaround comes at a steep cost in terms of errors, mutations, and lack of consistency – rendering Twist’s “chip” a self-defeating gimmick with no way to win, as any efficiencies are quickly destroyed by the workarounds required for its inability to make usable amounts of DNA.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bfeb-c0198a7c2ff9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Twist’s workaround to address their inability to make sufficient amounts of DNA – an amplification process called “tiling” – introduces quality problems like mutations and lack of consistency",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "630ed387-1bed-4cec-af84-462b43c88a48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "quote",
      "text": "“Twist has kind of tried to solve that problem by basically doing two things. They do what’s called “tiling,” which is - theoretically if you want to sequence a single segment of a genome with this hybridization capture method, you only need one piece of DNA to match up with that area of the genome that you want to sequence. The way Twist has gotten around the fact that they don’t have enough of that one piece of DNA to replicate out over many panels and/or have consistency with their results is by adding many, many pieces that target the same area of the genome that you want to sequence and that’s called tiling. They literally amplify out their panels using polymerase chain reaction. That kind of has solved their problems. Whenever you amplify out a panel, you have the risk of introducing mutations and each piece of DNA that you replicate. And if you do that too many times, your consistency of the use of that panel, the consistency of the data that would come out of using that panel, degrades because you’re introducing variation by amplifying it. But if you add enough oligos, you can make up for that, and that’s how Twist has kind of stayed relevant.” –IDT ex-regional sales manager, left recently",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62e81fca-1128-4275-bb59-56e2858d3ccd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Twist has kind of tried to solve that problem by basically doing two things. They do what’s called “tiling,” which is - theoretically if you want to sequence a single segment of a genome with this hybridization capture method, you only need one piece of DNA to match up with that area of the genome that you want to sequence. The way Twist has gotten around the fact that they don’t have enough of that one piece of DNA to replicate out over many panels and/or have consistency with their results is by adding many, many pieces that target the same area of the genome that you want to sequence and that’s called tiling. They literally amplify out their panels using polymerase chain reaction. That kind of has solved their problems. Whenever you amplify out a panel, you have the risk of introducing mutations and each piece of DNA that you replicate. And if you do that too many times, your consistency of the use of that panel, degrades because you’re introducing variation by amplifying it. But if you add enough oligos, you can make up for that, and that’s how Twist has kind of stayed relevant.” — IDT ex-regional sales manager, left recently",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bfeb-c5b9e8d5b18a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd7ba76f-2efc-41c4-89b0-11b646bb549a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Experts indicated that the workaround Twist uses to amplify the infinitesimal quantities of DNA produced by the chip is called “tiling” – a finger in the dike which is “how Twist has kind of stayed relevant”: “they literally amplify out their panels using polymerase chain reaction [PCR].” However, the workaround comes at a steep cost in terms of errors, mutations, and lack of consistency – rendering Twist’s “chip” a self-defeating gimmick with no way to win, as any efficiencies are quickly destroyed by the workarounds required for its inability to make usable amounts of DNA.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a8ea42d-5899-4d2e-aa73-62a499987a58",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 100,
      "from": 90,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ba084e17-8baa-48c4-95ae-b7f2113f8ae2",
      "evidence": "Analysis of Twist's financial struggles and industry implications",
      "position": 1,
      "objective": "Highlight the consequences of Twist's actions",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}